UCB's Latest Research in Epilepsy Care
UCB is dedicating its efforts to advancing research for individuals living with epilepsy by presenting a series of groundbreaking studies. With an emphasis on epilepsy treatments, UCB is showcasing 26 scientific abstracts, which include two oral presentations highlighting the company's commitment to improving the quality of life for people affected by epileptic conditions.
Focus Areas of Research
Among the studies presented, UCB discusses the findings from an open-label extension study about the long-term safety and efficacy of FINTEPLA (fenfluramine), particularly in children and adults diagnosed with Dravet syndrome or Lennox-Gastaut syndrome. These conditions require ongoing research due to their complexity and the severe challenges they pose in terms of management and care.
Insights on Developmental and Epileptic Encephalopathies
The data also shed light on developmental and epileptic encephalopathies (DEEs). A notable qualitative study highlights the diagnostic obstacles and advantages present in adult care settings. Caregivers participated in a survey that revealed the daily impacts of unpredictable seizures, showcasing the urgent need for comprehensive care strategies tailored to individual patient needs.
Defining Prolonged Seizures
UCB is also focusing on defining prolonged seizures and understanding their real-world impact. Ongoing research characterizes the experiences of both patients and caregivers dealing with prolonged seizures. The data points out unmet needs that can significantly impede quality of life, underlining the importance of addressing these challenges effectively.
The UCB Study Findings
In the open-label extension study, which recruited 412 patients who had participated in previous fenfluramine trials, the findings demonstrated sustained benefits and no new safety concerns. This showcases a commitment to safety while continuing to provide effective treatment options.
Addressing Diagnostic Gaps in DEEs
UCB's research emphasizes the diagnostic gaps in adult patients with DEEs. Interviews reveal that confirmed diagnoses enable enhanced holistic care, addressing critical healthcare challenges that improve the overall quality of life and communication among caregivers and healthcare providers.
Unpredictable Seizures in Daily Life
Results from a caregiver survey reflect that many caregivers face substantial daily challenges due to unpredictable seizures. The data shows that high incidences of disruptive seizures can lead to temporary losses in abilities, underscoring the need for more effective strategies in managing DEEs.
Prolonged Seizure Impacts on Quality of Life
Research characterizing patient experiences of prolonged seizures emphasizes the significant short-term and long-term negative impacts on quality of life. Real-world data reveal that individuals with epilepsy often experience severe anxiety and worry surrounding their seizures, which can lead to further medical emergencies.
Improving Management of Acute Seizure Emergencies
A qualitative study aimed at understanding the complete care process for acute seizure emergencies highlights the necessity for better outpatient guidelines. By enhancing outpatient care, UCB aims to empower patients and caregivers to manage seizures more effectively, potentially lowering the need for emergency interventions.
Future Directions in Research
UCB is pushing forward with innovative pipelines aimed at addressing the complexities associated with epilepsy. Their future studies will delve deeper into genetic therapies, emphasizing the transformative potential of early interventions for conditions like STXBP1 haploinsufficiency, which is crucial for long-term efficacy and patient care.
UCB Symposium at the International Epilepsy Congress
Scheduled for September 1 at the International Epilepsy Congress, UCB will hold a symposium to discuss the broader implications of DEEs in adulthood. This session aims to drive improvements in diagnosis, understanding treatment pathways, and addressing barriers to care, ultimately striving for better outcomes for individuals affected by epilepsy.
About UCB
UCB is a global biopharmaceutical company, headquartered in Brussels, Belgium, focused on the innovative development of treatments aimed at improving the lives of people suffering from severe diseases affecting the immune system and the central nervous system. With around 9,000 employees across about 40 countries, UCB generated significant revenue, further establishing itself as a leader in biopharmaceutical innovations. Committed to research in epilepsy, UCB remains dedicated to improving therapeutic outcomes for patients and their families through continuous advancements in medical science.
Frequently Asked Questions
What is UCB's focus in their latest epilepsy research?
UCB is focused on advancing innovations to improve care for individuals with epileptic conditions, emphasizing long-term safety and efficacy of treatments like FINTEPLA.
What are developmental and epileptic encephalopathies (DEEs)?
DEEs are severe forms of epilepsy that pose significant challenges for diagnosis and treatment, affecting both children and adults.
How does prolonged seizure impact quality of life?
Prolonged seizures can lead to substantial anxiety, emergency medical conditions, and lower overall quality of life for both patients and their caregivers.
What will UCB present at the International Epilepsy Congress?
UCB will showcase various studies focused on DEEs, prolonged seizures, and innovative strategies for improving care for epilepsy patients.
What is the aim of UCB's upcoming symposium?
The symposium aims to increase awareness and understanding of DEEs, focusing on enhancing diagnosis and addressing barriers in care to improve patient outcomes.
